William Marsh Rice University was granted a US patent on July 7, 2026 for a brain-computer interface that reaches the nervous system without opening the skull. The issued patent, US12673202B2, titled “Cortical subarachnoid and intra ventricular brain interfaces,” describes threading a microelectrode catheter to neural targets through the subarachnoid space — the fluid-filled layer around the brain and spinal cord. As a university assignee rather than a commercial device maker, Rice is best read here through the lens of its translational-research estate: this grant, and the two that issued alongside it the same week, mark where the institution’s bioengineering work is being converted into protectable IP.

The clinical premise of the hero grant is access. Conventional implanted neural interfaces often require open craniotomy to place electrodes on or in the brain. The Rice device is directed at avoiding that. Per the disclosure, a clinician performs a lumbar puncture to enter the spinal subarachnoid space and advances a microcatheter through that space; the catheter carries stimulating and recording electrodes configured for implantation into the spinal and intracranial subarachnoid space or into the ventricles of the brain. The independent claim pairs that microelectrode catheter with an implantable pulse generator, framing the invention as a complete stimulate-and-record system rather than a single electrode.

The present disclosure is directed to neural interface devices and methods that accesses the subarachnoid space to enable minimally invasive modulation and recording of neural structures.— Cortical subarachnoid and intra ventricular brain interfaces, US12673202B2

The other half of the disclosure is how the implant is powered, and it reflects the lab lineage behind the filing — lead inventor Jacob Robinson is known for magnetoelectric bioelectronics. Rather than a bulky battery, the described embodiments use an external field transmitter that emits an alternating magnetic field in the 20 kHz–1 MHz range to drive a magnetoelectric film at mechanical resonance, powering the implant wirelessly. The disclosure describes stimulation amplitudes of 12.0 V or greater and pulse widths on the order of 250 µs, and a magnetoelectric backscatter communication protocol for sending data back out. Wireless power delivered magnetoelectrically, minimally invasive catheter access, and backscatter telemetry are the three ideas the record ties together.

A university bioengineering estate

What situates this filing as part of an institutional research estate rather than a product roadmap is the company it keeps in Rice’s July 7 issued cohort. US12673132B2, from the Mikos lab, covers extrusion printing of biocompatible scaffolds — 3D-printed porous structures for bone and cartilage. US12673072B2, from the Veiseh lab, covers encapsulated cells expressing IL-12, an implantable cell-encapsulation construct for delivering that cytokine. A neural interface, a tissue-engineering scaffold, and a cell-therapy delivery construct do not describe one commercial line; they describe the output of separate laboratories under one university roof, each converting a distinct line of bioengineering research into a granted patent in the same week.

That distinction matters for how the hero grant should be read. For a company, a cohort like this might suggest a strategic direction. For a university, it more accurately reflects the breadth of a translational-research portfolio — the kind of estate that typically moves toward the clinic through licensing, startup formation, or sponsored collaboration rather than in-house manufacturing. The subarachnoid interface is the most system-level of the three, combining a delivery method, an electrode array, a wireless power scheme, and a data protocol into one claimed device, which makes it a natural anchor for the kind of translational partnership universities pursue.

Framed that way, the hero grant is a marker of where Rice’s neuroengineering work has matured to the point of a granted claim. Minimally invasive access through the subarachnoid space and magnetoelectric wireless power are both active frontiers in neurotechnology, and having an issued patent that combines them documents a specific technical position rather than a market claim. The scaffold and cell-encapsulation grants extend that documentation across regenerative medicine and immunotherapy, sketching an institution with granted IP spanning neural interfaces, printed tissue, and encapsulated-cell therapeutics.

The technical choices in the hero grant also help explain why it reads as a research milestone rather than a finished product. Accessing neural targets through the subarachnoid space borrows a route that clinicians already use for spinal anesthesia and diagnostic taps, which is part of what makes the approach minimally invasive; the engineering challenge is advancing a catheter carrying functional electrodes along that route and placing them where they can both stimulate and record. Powering such a device without a battery is the second hard problem, and the magnetoelectric approach — an external alternating magnetic field driving a film at mechanical resonance — is a way to deliver energy through tissue without the heating and alignment constraints of some other wireless schemes. The disclosed backscatter protocol closes the loop by letting the implant return data over the same magnetoelectric channel. Each of these is an area of active academic inquiry, and combining them in a single granted claim documents that the pieces have been brought together at least on paper.

None of this speaks to how broad any claim will prove or whether a given device reaches patients — a grant records what has been claimed, not what has been built or licensed. But as a window into an academic estate, Rice’s July 7 cohort is coherent: three laboratories, three modalities, and a lead neural-interface grant that reflects a translational research program working to reach the brain without opening the skull.